Clene Inc. Advances Toward NDA Submission for ALS Treatment CNM-Au8, Extends Financial Runway
Clene Inc. is preparing to submit a New Drug Application for its ALS treatment candidate CNM-Au8 by year-end 2025 while securing financial stability through recent financing that extends its cash runway into early 2026.
Clene Inc. (NASDAQ: CLNN) has announced significant progress toward regulatory submission for its lead neurodegenerative disease treatment while strengthening its financial position. The late clinical-stage biopharmaceutical company reported plans to submit a New Drug Application for CNM-Au8 in amyotrophic lateral sclerosis by the end of 2025, marking a critical milestone in the development of this innovative therapy.
The company's recent Type C meeting with the U.S. Food and Drug Administration focused on aligning statistical methodology for analyzing neurofilament light biomarker changes, an important step in validating the treatment's efficacy. Additional FDA meetings scheduled for the third quarter of 2025 will address ALS survival benefit data and multiple sclerosis development plans, providing crucial regulatory guidance for both programs.
CNM-Au8 represents a novel approach to treating neurodegenerative diseases as an oral suspension of gold nanocrystals designed to restore neuronal health by improving energy metabolism. The treatment's mechanism focuses on mitochondrial health and neuronal function protection, addressing fundamental aspects of conditions like ALS and MS. The company expects analysis of neurofilament light biomarker data from the NIH-sponsored Expanded Access Program in early fourth quarter 2025, which could provide additional validation of the treatment's biological effects.
Financially, Clene reported $7.3 million in cash and cash equivalents as of June 30, 2025, supplemented by recent financing that extends the company's cash runway into the first quarter of 2026. This financial stability provides the necessary resources to complete the NDA submission process and continue development activities without immediate funding concerns. The extended runway ensures that Clene can maintain operational continuity through key regulatory milestones and potential approval processes.
The progress toward NDA submission and extended financial positioning demonstrate Clene's strategic execution in advancing CNM-Au8 through late-stage development. For investors and patients following neurodegenerative disease treatments, these developments represent meaningful steps toward potentially bringing a new therapeutic option to market for ALS patients who currently have limited treatment choices available.